Long-term survival rates of patients with nasopharyngeal carcinoma treated by radiochemotherapy: a retrospective cohort study

被引:6
作者
Kazemian, Ali [1 ,2 ]
Ghalehtaki, Reza [1 ,2 ]
Farazmand, Borna [1 ]
Taherioun, Maryam [2 ]
Razmkhah, Mahdieh [2 ]
Khalili, Nastaran [3 ,4 ]
Farhan, Farshid [2 ]
Aghili, Mahdi [1 ,2 ]
Esmati, Ebrahim [2 ]
机构
[1] Univ Tehran Med Sci, Radiat Oncol Res Ctr, Canc Res Inst, Tehran, Iran
[2] Univ Tehran Med Sci, Canc Inst, Dept Radiat Oncol, Imam Khomeini Hosp Complex, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[4] Universal Sci Educ & Res Network USERN, Canc Immunol Project, Tehran, Iran
关键词
Chemoradiation; Head and neck cancer; Iran; Nasopharyngeal cancer; Conformal radiotherapy; INTENSITY-MODULATED RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; INDUCTION CHEMOTHERAPY; MULTICENTER; OUTCOMES; PHASE-3; CANCER;
D O I
10.1186/s43163-022-00212-2
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Nasopharyngeal cancer (NPC) is showing an increasing incidence in Iran. Radiation is the main treatment of this cancer. Use of new techniques such as intensity-modulated radiotherapy (IMRT) is on the rise. Here, we aimed to evaluate the oncological outcomes of NPC patients treated with three-dimensional conformal radiotherapy (3DCRT) for a more reliable comparison with IMRT in the future. Results: We reviewed the medical records of 106 patients with NPC treated by definitive radiotherapy from 2007 to 2016. Patients were treated with 70 Gy in 2-Gy fractions. Twenty-one patients died during the follow-up period. Twenty-nine patients suffered from locoregional or distant recurrences. Of these, 6 recurred after 2 years of treatment completion. The 2-year and 5-year overall survival rates were 81% and 76%, respectively. The 2-year and 5-year progression-free survival rates were 72% and 63%, respectively. The 5-year locoregional recurrence and distant metastasis-free survival rates were 68% and 69%, respectively. Conclusion: Due to high survival rates of NPC and the importance of receiving planned total dose of RT, the treatment-related toxicity and quality of life are critical considerations both for patients during active treatment and for survivors.
引用
收藏
页数:7
相关论文
共 20 条
[1]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[2]   Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype [J].
Barnett, Gillian C. ;
West, Catherine M. L. ;
Dunning, Alison M. ;
Elliott, Rebecca M. ;
Coles, Charlotte E. ;
Pharoah, Paul D. P. ;
Burnet, Neil G. .
NATURE REVIEWS CANCER, 2009, 9 (02) :134-142
[3]   Nasopharyngeal carcinoma [J].
Chan, A. T. C. .
ANNALS OF ONCOLOGY, 2010, 21 :308-312
[4]   Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial [J].
Chen, Lei ;
Hu, Chao-Su ;
Chen, Xiao-Zhong ;
Hu, Guo-Qing ;
Cheng, Zhi-Bin ;
Sun, Yan ;
Li, Wei-Xiong ;
Chen, Yuan-Yuan ;
Xie, Fang-Yun ;
Liang, Shao-Bo ;
Chen, Yong ;
Xu, Ting-Ting ;
Li, Bin ;
Long, Guo-Xian ;
Wang, Si-Yang ;
Zheng, Bao-Min ;
Guo, Ying ;
Sun, Ying ;
Mao, Yan-Ping ;
Tang, Ling-Long ;
Chen, Yu-Ming ;
Liu, Meng-Zhong ;
Ma, Jun .
LANCET ONCOLOGY, 2012, 13 (02) :163-171
[5]   Nasopharyngeal carcinoma [J].
Chua, Melvin L. K. ;
Wee, Joseph T. S. ;
Hui, Edwin P. ;
Chan, Anthony T. C. .
LANCET, 2016, 387 (10022) :1012-1024
[6]   The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[7]   Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy - A longitudinal study [J].
Fang, Fu-Min ;
Chien, Chih-Yen ;
Tsai, Wen-Ling ;
Chen, Hui-Chun ;
Hsu, Hsuan-Chih ;
Lui, Chun-Chung ;
Huang, Tai-Lin ;
Huang, Hsuan-Ying .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (02) :356-364
[8]   Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy? [J].
Hennessy, Maeve A. ;
Morris, Patrick G. .
ANTI-CANCER DRUGS, 2020, 31 (02) :97-100
[9]   Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3 [J].
Kawahira, Masahiro ;
Yokota, Tomoya ;
Hamauchi, Satoshi ;
Onozawa, Yusuke ;
Ogawa, Hirofumi ;
Onoe, Tsuyoshi ;
Kamijo, Tomoyuki ;
Iida, Yoshiyuki ;
Nishimura, Tetsuo ;
Onitsuka, Tetsuro ;
Yasui, Hirofumi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (08) :705-712
[10]   Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy [J].
Le, Quynh Thu ;
Colevas, A. Dimitrios ;
OSullivan, Brian ;
Lee, Anne W. M. ;
Lee, Nancy ;
Ma, Brigette ;
Siu, Lillian L. ;
Waldron, John ;
Lim, Chwee-Ming ;
Riaz, Nadeem ;
Lynn, Jean ;
Malik, Shakun .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (07) :655-663